Insider Trading Activity Abbott Laboratories (NYSE:ABT) – Insider Bought 15,580 shares of Stock

ME Staff

8 years ago

Insider Trading Activity For Abbott Laboratories (NYSE:ABT)

Brian J Blaser , Insider of Abbott Laboratories (NYSE:ABT) reportedly Bought 15,580 shares of the company’s stock at an average price of 38.45 for a total transaction amount of $599,051.00 SEC Form

Insider Trading History For Abbott Laboratories (NYSE:ABT)

On 2/1/2013 William A Osborn, Director, bought 10,000 with an average share price of $33.86 per share and the total transaction amounting to $338,600.00.

On 6/7/2013 Heather L Mason, SVP, sold 12,000 with an average share price of $37.01 per share and the total transaction amounting to $444,120.00.

On 10/30/2013 Jaime Contreras, SVP, sold 25,368 with an average share price of $36.85 per share and the total transaction amounting to $934,810.80.

On 11/7/2013 Stephen Fussell, EVP, sold 10,466 with an average share price of $37.59 per share and the total transaction amounting to $393,416.94.

On 12/6/2013 Jean-Yves Pavee, SVP, sold 5,855 with an average share price of $37.46 per share and the total transaction amounting to $219,328.30.

On 1/29/2014 Michael Warmuth, EVP, sold 11,430 with an average share price of $36.21 per share and the total transaction amounting to $413,880.30.

On 2/18/2014 John Landgraf, EVP, sold 1,583 with an average share price of $39.10 per share and the total transaction amounting to $61,895.30.

Analyst Ratings For Abbott Laboratories (NYSE:ABT)
These are 6 Hold Ratings, 15 Buy RatingsThe current consensus rating for Abbott Laboratories (NYSE:ABT) is Buy (Score: 2.71) with a consensus target price of $46.64 , a potential (21.97% upside)

Analyst Ratings History For Abbott Laboratories (NYSE:ABT)

On 4/23/2015 JPMorgan Chase & Co. Boost Price Target of rating Neutral with a price target of $46.00 to $48.00
On 5/26/2015 Evercore ISI Initiated Coverage of rating Buy with a price target of $54.00
On 5/27/2015 Evercore Partners Inc. Initiated Coverage of rating Buy with a price target of $54.00
On 1/4/2016 Morgan Stanley Downgraded rating Overweight to Equal Weight with a price target of $50.00
On 1/29/2016 William Blair Downgraded rating Outperform to Market Perform
On 1/29/2016 Goldman Sachs Group Inc. Lower Price Target of rating Neutral with a price target of $44.00 to $40.00
On 1/29/2016 Raymond James Financial Inc. Lower Price Target of rating Outperform with a price target of $46.00 to $42.00

Dividend Information For Abbott Laboratories (NYSE:ABT)
Abbott Laboratories (NYSE:ABT) pays an annual dividend of $1.04 with a yield of 2.72% and an average dividend growth of -21.80% (3 Year Average).

Dividend History For Abbott Laboratories (NYSE:ABT)

On 12/14/2012 Abbott Laboratories announced a quarterly dividend of $0.14 0.86% with an ex dividend date of 1/11/2013 which will be payable on 2/15/2013.

On 2/15/2013 Abbott Laboratories announced a quarterly dividend of $0.14 1.61% with an ex dividend date of 4/11/2013 which will be payable on 5/15/2013.

On 6/14/2013 Abbott Laboratories announced a quarterly dividend of $0.14 1.52% with an ex dividend date of 7/11/2013 which will be payable on 8/15/2013.

On 9/12/2013 Abbott Laboratories announced a quarterly dividend of $0.14 1.61% with an ex dividend date of 10/10/2013 which will be payable on 11/15/2013.

On 10/16/2013 Abbott Laboratories announced a quarterly dividend of $0.22 2.37% with an ex dividend date of 1/13/2014 which will be payable on 2/15/2014.

On 2/21/2014 Abbott Laboratories announced a quarterly dividend of $0.22 2.26% with an ex dividend date of 4/11/2014 which will be payable on 5/15/2014.

On 6/13/2014 Abbott Laboratories announced a quarterly dividend of $0.22 2.21% with an ex dividend date of 7/11/2014 which will be payable on 8/15/2014.

About Abbott Laboratories (NYSE:ABT)
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Recent Trading Activity for Abbott Laboratories (NYSE:ABT)
Shares of Abbott Laboratories closed the previous trading session at 38.24 up +0.05 0.13% with 9,190,942 shares trading hands.